Starling Oncology (STLNW) Inventory Average (2022 - 2026)

Starling Oncology (STLNW) has reported Inventory Average for 5 consecutive years, with $22.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Inventory Average rose 57.69% year-over-year to $22.2 million; the trailing twelve-month figure through Jun 2026 stood at $22.2 million (up 57.69% YoY), and the FY2025 full-year result was $13.5 million, up 13.48% from the prior year.
• Inventory Average climbed to $22.2 million in Q2 2026 per STLNW's latest filing, from $20.6 million in the prior quarter.
• Across five years, Inventory Average topped out at $22.2 million in Q2 2026 and bottomed at $7.1 million in Q1 2022.
• Historically, Inventory Average has averaged $12.7 million across 5 years, with a median of $11.3 million in 2023.
• The sharpest annual moves came in 2024 and 2026: Inventory Average decreased 22.08% in 2024, then surged 84.21% in 2026.
• Over 5 years, Inventory Average stood at $9.6 million in 2022, then soared by 34.09% to $12.9 million in 2023, then fell by 22.08% to $10.1 million in 2024, then surged by 77.5% to $17.9 million in 2025, then increased by 23.89% to $22.2 million in 2026.
• According to Business Quant data, Inventory Average over the past three periods registered $22.2 million, $20.6 million, and $17.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.